Table 4 shows that the drugs targeting EDNRA are mostly antagonists. EDNRA (Endothelin receptor) antagonists ambrisentan, bosentan, and macitentan have been evaluated as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes [65]. The efficacy of macitentan, a dual endothelin receptor antagonist, has been evaluated in treating the brain metastases of breast and lung cancers in mice [66]. The use of macitentan, a dual endothelin receptor antagonist, in combination with temozolomide, may lead to glioblastoma regression and long-term survival in mice [67]. Here, EDNRA is linked to lung cancer.